twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2007
vol. 109
 
Share:
Share:
abstract:
Case report

The evaluation of the efficacy of treatment in glaucoma associated with Sturge-Weber syndrome

Monika Oziębło-Kupczyk
1
,
Beata Urban
1
,
Małgorzata Mrugacz
1
,
Alina Bakunowicz-Łazarczyk
1

  1. Z Kliniki Okulistyki Dziecięcej Akademii Medycznej w Białymstoku
Klinika Oczna 2007, 109 (1): 46-48
Online publish date: 2007/03/23
View full text Get citation
 
Purpose
To estimate the efficiency of glaucoma treatment in Sturge-Weber syndrome.

Material and methods
4 patients with Sturge-Weber syndrome and the consecutive glaucoma seen at the Department of Ophthalmology in Bialystok between the years 1999-20005, were reviewed. Glaucoma associated with Sturge-Weber syndrome was diagnosed at the age of 6 months in 1 patient, of 10-11 years in 2 patients and of 14 years in 1 patients. All patients underwent surgery. 2 eyes underwent trabeculectomy and 2 eyes had nonpenetrating deep sclerectomy with SKGel implant.

Results
Before the surgery the intraocular pressure was 35.2 mmHg (range from 25 to 48 mmHg). All patients required antiglaucoma medications after surgery to keep intraocular pressure less than 22 mmHg. After surgery the mean intraocular pressure was 26.25 mmHg (range from 22 to 32 mmHg). 2 patients required 2 medications: Betoptic, and/or Trusopt, and/or Xalatan and 2 patients required 1 medication. After antiglaucoma medications mean IOP was 15.2 mmHg (range from 12 to 18 mmHg).

Conclusions
The results of therapy for glaucoma associated with the Sturge-Weber syndrome are often disappointing.

keywords:

phacomatosis, consecutive glaucoma, trabeculectomia

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.